Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...
Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...
With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will ...
“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.
Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the ...
After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining ...
A new mental health-driven biotech has arrived in Syremis Therapeutics. | Founded by a team of neuropsychiatric-focused Teva ...
Earlier this month, Medtronic received a new approval from the FDA for its decades-old liquid embolic system, extending its ...
GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory ...
Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...
After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical ...
After reportedly flirting with going public for years, the artificial intelligence-powered drug developer Insilico Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results